Danavorexton

Danavorexton (TAK-925) is a potent, selective, brain-penetrant, nonpeptide orexin 2 receptor (OX2R) agonist developed by Takeda Pharmaceutical Company as the first small-molecule orexin receptor agonist to enter clinical development. Identified through high-throughput screening and optimized through a medicinal chemistry campaign that converted a micromolar-potency hit (EC50 570 nM) into a low-nanomolar agonist (EC50 5.5 nM in calcium mobilization assays) with greater than 18,000-fold selectivity for human OX2R over OX1R, danavorexton is a (2R,3S)-piperidine carbamate bearing a cis-4-phenylcyclohexyl ether and a methylsulfonamide pharmacophore. The compound adopts a compact U-shaped conformation that engages the OX2R orthosteric pocket through a critical hydrogen bond between the sulfonamide nitrogen and Gln134(3.32), as resolved by two cryo-electron microscopy structures of the OX2R-G protein complex at 3.2 to 3.3 angstrom resolution. Selectivity over OX1R arises from subtle differences at only two residues (Thr111(2.61) and Thr135(3.33) in OX2R versus Ser and Ala at the corresponding positions in OX1R) that alter steric complementarity and desolvation within the orthosteric pocket. Administered exclusively by intravenous infusion, danavorexton has completed Phase 1 clinical studies in narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, obstructive sleep apnea with residual excessive daytime sleepiness, and opioid-induced respiratory depression, collectively enrolling over 150 participants across six registered trials. In a multiple-rising-dose study (NCT03748979), danavorexton at 44 mg intravenous over 9 hours produced maximal Maintenance of Wakefulness Test sleep latency (40 minutes in all sessions) in all narcolepsy type 1 participants, reduced cataplexy episodes to zero during infusion, and normalized the Epworth Sleepiness Scale score from a baseline of 18.6 to 0.0 by day 7. Comparable wakefulness-promoting effects were demonstrated in narcolepsy type 2, idiopathic hypersomnia (placebo-adjusted sleep latency improvement of 29.4 minutes), and sleep-deprived healthy volunteers (sleep latency of 31.8 minutes at 112 mg versus 9.2 minutes on placebo). In a crossover study of remifentanil-induced respiratory depression, danavorexton reversed respiratory depression (minute volume increase of 13.0 L/min at 19 mg, p < 0.001) and sedation without reversing opioid analgesia. Human pharmacokinetics are characterized by dose-proportional plasma concentrations, a terminal half-life of approximately 3 to 5 hours, negligible accumulation with daily 9-hour infusions, and a cerebrospinal fluid-to-plasma concentration ratio of approximately 2.8 percent. The compound is well tolerated across all studied populations. The most common drug-related adverse events are pollakiuria (urinary frequency), transient blood pressure elevation, insomnia, headache, and dizziness, all predominantly mild in severity. No hepatotoxicity has been observed, distinguishing danavorexton from its oral successor TAK-994 (firazorexton), which demonstrated exceptional efficacy in a Phase 2 narcolepsy trial but was discontinued following drug-induced liver injury in three participants meeting Hy's law criteria. The second-generation oral OX2R agonist TAK-861 (oveporexton), structurally distinct from both danavorexton and TAK-994, has completed a positive Phase 2 trial with no hepatic signal and is advancing toward Phase 3 registration. This monograph reviews the medicinal chemistry, structural biology, receptor pharmacology, pharmacokinetics, preclinical and clinical evidence base, adverse event profile, sourcing and handling considerations, and a comparative assessment of danavorexton against four alternative agents in the narcolepsy and excessive daytime sleepiness pharmacotherapy space (TAK-994, TAK-861, pitolisant, solriamfetol) on five competency standards. Danavorexton is not approved for any indication in any jurisdiction. It is an investigational compound available in research-grade preparations; investigators should obtain analytical confirmation of identity and purity on every lot.